Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Davidowitz, RA"'
Autor:
Davidowitz, RA, Selfors, LM, Iwanicki, MP, Elias, KM, Karst, A, Piao, H, Ince, TA, Drage, MG, Dering, J, Konecny, GE, Matulonis, U, Mills, GB, Slamon, DJ, Drapkin, R, Brugge, JS
Publikováno v:
The Journal of clinical investigation, vol 124, iss 6
Davidowitz, RA; Selfors, LM; Iwanicki, MP; Elias, KM; Karst, A; Piao, H; et al.(2014). Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance. Journal of Clinical Investigation, 124(6), 2611-2625. doi: 10.1172/JCI69815. UCLA: Retrieved from: http://www.escholarship.org/uc/item/4q50b4b6
Davidowitz, RA; Selfors, LM; Iwanicki, MP; Elias, KM; Karst, A; Piao, H; et al.(2014). Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance. Journal of Clinical Investigation, 124(6), 2611-2625. doi: 10.1172/JCI69815. UCLA: Retrieved from: http://www.escholarship.org/uc/item/4q50b4b6
Metastatic dissemination of ovarian tumors involves the invasion of tumor cell clusters into the mesothelial cell lining of peritoneal cavity organs; however, the tumor-specific factors that allow ovarian cancer cells to spread are unclear. We used a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::77edaf11f963ee4aa2dfaad5e2084ea2
https://escholarship.org/uc/item/4q50b4b6
https://escholarship.org/uc/item/4q50b4b6
Autor:
Davidowitz, Rachel Alexis
Metastatic dissemination of ovarian tumors involves the invasion of multi-cellular tumor cell clusters into the mesothelial cell lining of organs in the peritoneal cavity. We developed an in vitro assay that models this initial step of ovarian cancer
Externí odkaz:
http://dissertations.umi.com/gsas.harvard:10719
http://nrs.harvard.edu/urn-3:HUL.InstRepos:11157454
http://nrs.harvard.edu/urn-3:HUL.InstRepos:11157454
Autor:
Labidi-Galy SI; 1] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA [2] Harvard Medical School, Boston, MA, USA., Clauss A; 1] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA [2] Harvard Medical School, Boston, MA, USA., Ng V; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Duraisamy S; 1] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA [2] Harvard Medical School, Boston, MA, USA., Elias KM; 1] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA [2] Harvard Medical School, Boston, MA, USA [3] Division of Gynecologic Oncology, Brigham and Women's Hospital, Boston, MA, USA., Piao HY; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Bilal E; The Cancer Institute of New Jersey, Robert Wood Johnson Medical School-University of Medicine and Dentistry of New Jersey, New Brunswick, NJ, USA., Davidowitz RA; Department of Cell Biology, Harvard Medical School, Boston, MA, USA., Lu Y; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Badalian-Very G; 1] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA [2] Harvard Medical School, Boston, MA, USA., Györffy B; Research Laboratory of Pediatrics and Nephrology, Hungarian Academy of Sciences, Budapest, Hungary., Kang UB; 1] Harvard Medical School, Boston, MA, USA [2] Blais Proteomics Center, Dana-Farber Cancer Institute, Boston, MA, USA., Ficarro S; 1] Harvard Medical School, Boston, MA, USA [2] Blais Proteomics Center, Dana-Farber Cancer Institute, Boston, MA, USA., Ganesan S; The Cancer Institute of New Jersey, Robert Wood Johnson Medical School-University of Medicine and Dentistry of New Jersey, New Brunswick, NJ, USA., Mills GB; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Marto JA; 1] Harvard Medical School, Boston, MA, USA [2] Blais Proteomics Center, Dana-Farber Cancer Institute, Boston, MA, USA., Drapkin R; 1] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA [2] Harvard Medical School, Boston, MA, USA [3] Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Publikováno v:
Oncogene [Oncogene] 2015 Jan 15; Vol. 34 (3), pp. 373-83. Date of Electronic Publication: 2014 Jan 27.
Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance.
Autor:
Davidowitz RA, Selfors LM, Iwanicki MP, Elias KM, Karst A, Piao H, Ince TA, Drage MG, Dering J, Konecny GE, Matulonis U, Mills GB, Slamon DJ, Drapkin R, Brugge JS
Publikováno v:
The Journal of clinical investigation [J Clin Invest] 2014 Jun; Vol. 124 (6), pp. 2611-25. Date of Electronic Publication: 2014 Apr 24.
Publikováno v:
Journal of visualized experiments : JoVE [J Vis Exp] 2012 Feb 17 (60). Date of Electronic Publication: 2012 Feb 17.
Autor:
Iwanicki MP; Department of Cell Biology, Harvard Medical School, Boston, 02115 MA, USA., Davidowitz RA, Ng MR, Besser A, Muranen T, Merritt M, Danuser G, Ince TA, Brugge JS
Publikováno v:
Cancer discovery [Cancer Discov] 2011 Jul; Vol. 1 (2), pp. 144-57.